TXMD - TherapeuticsMD, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5658.54M
Enterprise Value 3673.46M
Trailing P/E N/A
Forward P/E 1-7.38
PEG Ratio (5 yr expected) 1-0.19
Price/Sales (ttm)35.43
Price/Book (mrq)80.29
Enterprise Value/Revenue 336.23
Enterprise Value/EBITDA 6-4.44

Trading Information

Stock Price History

Beta (3Y Monthly) 2.23
52-Week Change 3-53.80%
S&P500 52-Week Change 31.68%
52 Week High 36.9400
52 Week Low 31.8200
50-Day Moving Average 32.4677
200-Day Moving Average 33.8205

Share Statistics

Avg Vol (3 month) 33.63M
Avg Vol (10 day) 33.26M
Shares Outstanding 5241.22M
Float 198.72M
% Held by Insiders 117.76%
% Held by Institutions 178.61%
Shares Short (Jul 31, 2019) 482.8M
Short Ratio (Jul 31, 2019) 434.86
Short % of Float (Jul 31, 2019) 447.11%
Short % of Shares Outstanding (Jul 31, 2019) 434.33%
Shares Short (prior month Jun 28, 2019) 486.6M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2100/1
Last Split Date 3Oct 3, 2011

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019


Profit Margin 0.00%
Operating Margin (ttm)-818.91%

Management Effectiveness

Return on Assets (ttm)-45.47%
Return on Equity (ttm)-396.41%

Income Statement

Revenue (ttm)18.59M
Revenue Per Share (ttm)0.08
Quarterly Revenue Growth (yoy)61.50%
Gross Profit (ttm)13.36M
EBITDA -151.83M
Net Income Avi to Common (ttm)-169.74M
Diluted EPS (ttm)-0.7150
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)182.85M
Total Cash Per Share (mrq)0.76
Total Debt (mrq)197.77M
Total Debt/Equity (mrq)2,443.43
Current Ratio (mrq)5.17
Book Value Per Share (mrq)0.03

Cash Flow Statement

Operating Cash Flow (ttm)-150.89M
Levered Free Cash Flow (ttm)-114.98M